Wednesday, July 9, 2008

Spotlight on emerging Columbus Tech Companies

CellSignals, Inc.

CellSignals applies its proprietary technology in chiral synthesis to develop lipid mediators pertinent to intracellular signal transduction and cancer biology. Currently CellSignals’ product line has grown to more than 40 chemicals covering a variety of inositol polyphosphates and phosphatidylinositol polyphosphates. Our customers are cancer researchers from all over the world.
In addition, employing our synthetic expertise and current strategic drug design based on molecular modeling, CellSignals is actively developing small-molecules, orally bio-available therapeutics for the treatments of breast, skin cancers, and leukemia. Several potential therapeutic agents synthesized in our laboratory have proven effective in vitro. With this new development, CellSignals is proud to embrace its new role in drug discovery.


Develops and sells skin biopsy, closure and repair solutions that markedly improve patient outcomes and enhance practice economics for dermatology, cosmetic surgery. The technology was developed by surgeons at The Cleveland Clinic and is fully owned by CleveX.

Labels: , , ,


Post a Comment

Subscribe to Post Comments [Atom]

<< Home